Compile Data Set for Download or QSAR
maximum 50k data
Found 220 Enz. Inhib. hit(s) with all data for entry = 3162
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393276(5-(3,4- difluorobenzenesulfon- amidomethyl)-6- met...)
Affinity DataIC50:  16.2nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393246(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-6...)
Affinity DataIC50:  19.6nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393274(5-(3- chlorobenzenesulfon- midomethyl)-6- methyl-N...)
Affinity DataIC50:  39.5nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393080(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  61nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393273(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-6...)
Affinity DataIC50:  87.8nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393074(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  108nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393097(6-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  108nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393275(5-(4- fluorobenzenesulfon- amidomethyl)-6- methyl-...)
Affinity DataIC50:  137nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393277(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  169nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393194(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  180nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393059(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  187nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393066(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  204nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393226(5-(3,4- difluorobenzenesulfon- amidomethyl)-N-[(2-...)
Affinity DataIC50:  219nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393206(5-(3,4- difluorobenzenesulfon- amidomethyl)-N-[(2-...)
Affinity DataIC50:  313nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393058(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  347nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393268(5-(3,5- difluorobenzenesulfon- amidomethyl)-6- met...)
Affinity DataIC50:  366nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393101(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  439nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393266(5-(3,4- dichlorobenzenesulfon- amidomethyl)-6- met...)
Affinity DataIC50:  494nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393188(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  624nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393096(6-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  630nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393106(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  757nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393063(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  758nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393095(6-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  790nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393239(5-(3- chlorobenzenesulfon- amidomethyl)-N-[(2- met...)
Affinity DataIC50:  839nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393183(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  850nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393061(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  929nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393271(5-(4-chloro-3- fluorobenzenesulfon- amidomethyl)-6...)
Affinity DataIC50:  1.02E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393176(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  1.02E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393203(5-(3- chlorobenzenesulfon- amidomethyl)-N-[(2- met...)
Affinity DataIC50:  1.04E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393204(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  1.10E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393123(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  1.25E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393136(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  1.69E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393103(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  1.70E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393083(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  1.95E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393143(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  2.00E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393104(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  2.10E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393192(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  2.18E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393098(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  2.40E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393187(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  2.43E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393146(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  2.55E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393175(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  2.83E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393228(5-(4- fluorobenzenesulfon- amidomethyl)-N-[(2- met...)
Affinity DataIC50:  2.84E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393142(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  3.02E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393105(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  3.09E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393041(5-(3-chloro-4- fluorobenzenesulfon- midomethyl)-N-...)
Affinity DataIC50:  3.37E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393259(N-[(2-methyl-1,3- thiazol-5-yl)methyl]-5- (thiophe...)
Affinity DataIC50:  3.77E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393233(N-[(2-methyl-1,3- thiazol-5-yl)methyl]-5- (thiophe...)
Affinity DataIC50:  4.02E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393042(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  4.59E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393180(5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N...)
Affinity DataIC50:  4.84E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2A(Homo sapiens (Human))
Luc Therapeutics

US Patent
LigandPNGBDBM393241(5-(4- fluorobenzenesulfon- midomethyl)-N-[(2- meth...)
Affinity DataIC50:  5.51E+3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2A (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 220 total ) | Next | Last >>
Jump to: